In this podcast from ESMO 2023, UROONCO BCa associate editor Dr. Laura Mertens (NL) talks with Dr. Michiel Van Der Heijden (NL) on his abstract “Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial”.
Dr. Van Der Heijden shares details on the design of the trial and the late-breaking results that he presented at ESMO 2023.
Primary endpoints were met with overall survival (OS) and progression-free survival (PFS). Dr. Van Der Heijden also talks about the secondary endpoints, such as complete response rate, durability.
For more details on this trial, you can read this abstract on the UROONCO Bladder Cancer educational platform.